The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 6 May 2026•Updated 7 May 2026•

1 min read

Anavex Life Sciences Names Terrie Kellmeyer Interim CEO After Missling Resignation

Portrait of Terrie Kellmeyer as Interim CEO of Anavex Life Sciences with biotech graphics and corporate documents.

Key Facts

1Anavex Life Sciences Board of Directors appointed Terrie Kellmeyer, PhD, as Interim Chief Executive Officer.

27 days ago

Version History

Version 127 days ago

The Board of Directors of Anavex Life Sciences has appointed Terrie Kellmeyer, PhD, as the company's Interim Chief Executive Officer. This leadership transition follows the departure of former CEO Christopher Missling on April 30, 2026. Notably, Missling’s exit occurred after the Board of Directors formally requested his resignation, signaling a significant shift in corporate governance. Dr. Kellmeyer will now oversee the clinical-stage biopharmaceutical firm’s operations during this interim period. Market participants are closely monitoring the situation, as forced executive departures often raise concerns regarding internal stability and strategic continuity. The company has not yet detailed the specific reasons behind the Board's decision to seek new leadership.